Robin Besuyen, MD

PDF

 

Europital has done a great job in providing medical monitors to our phase 2 program in psoriatic arthritis and axial spondyloarthritis. The team of physicians was very well trained to perform safety oversight and medical data review. They have significantly contributed to the quality of the data in these studies. Over the course of time, Europital has been a true partner for Galapagos Clinical Development, committed, flexible and with high quality support.

Robin Besuyen, MD
Clinical Development Leader Inflammation
Galapagos

 

 

Nathalie Théron, PhD

PDF

 

Dear Europital,

I would like to take this opportunity to thank you and your team for the hard work and support on the Peruse study.

Particularly, Mohamed for his valuable contribution on the Peruse study! Mohamed, it has been a very high pleasure to work with you and on behalf of the Roche team, I would like to sincerely thank you. You did a great job and you played a key role in the success of the Peruse study.

Many thanks to all of you, I really hope to work again with you on other projects.

Kind regards

Nathalie Théron, PhD
Global Study Manager (GSM)
PD Clinical Operations (PDG) Oncology
Pharmaceutical Division
F.Hoffmann-La Roche Ltd.,
Basel, Switzerland

 

 

Sally Adams, PhD

PDF

 

Since 2015, Europital’s CEO and Chief Medical Officer, Dr Mohamed El Malt, has provided medical advice and support for Scancell’s ImmunoBody® clinical trials and has recently been involved in the design of a new trial protocol relating to its Moditope® platform. It has been a pleasure working with him. Mohamed and his team of physicians are knowledgeable, thorough and completely reliable, as well as being helpful, open and collaborative.

Sally Adams, PhD
Development Director

Scancell Ltd
Oxford, United Kingdom

 

 

CASE STUDY: Antiviral Study in Infants

PDF

 

A medium-size biotech is developing a novel treatment against Respiratory Syncytial Virus. They started their Phase I First-in-Infant study and, within the same time period, planned for the Phase II study in the same program.

 

 

  

 

 

 

 

 

 

Message from the Europital CEO

To our Clients, Staff and Partners

Since the reporting of first cases of COVID-19 infection, Europital management has kept a close eye on the evolvement of this novel virus and continuously assessed the risk associated with the spread of infection in other parts of the world...  [read more]